Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EPIX Stock Forecast 2026-2027
$0.20
Current Price
$9.52M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to EPIX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
EPIX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-88.3%
1 Year Change
0.0%
Year-to-Date Change
-96.9%
From 52W High of $6.45
+11.8%
From 52W Low of $0.18
📊 TOP ANALYST CALLS
Did EPIX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Essa Pharma is one of their latest high-conviction picks.
Latest EPIX Stock Price Targets & Analyst Predictions
EPIX has shown a year-to-date change of 0.0% and a 1-year change of -88.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for EPIX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EPIX Analyst Ratings
0
Buy
1
Hold
0
Sell
EPIX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.20
Latest EPIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EPIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 4, 2024 | Piper Sandler | Joseph Catanzaro | Neutral | Downgrade | $2.00 |
| Nov 4, 2024 | Oppenheimer | Leland Gershell | Perform | Downgrade | $N/A |
| Nov 1, 2024 | Jones Trading | Soumit Roy | Hold | Downgrade | $N/A |
| May 16, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $17.00 |
| Dec 13, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Reiterates | $17.00 |
| Aug 9, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Reiterates | $17.00 |
| Jun 26, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Assumes | $17.00 |
| May 12, 2022 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $20.00 |
| Aug 17, 2021 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $22.00 |
| Mar 4, 2021 | Piper Sandler | Overweight | Initiates | $N/A | |
| Feb 25, 2021 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $32.00 |
| Feb 11, 2021 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $36.00 |
| Jan 11, 2021 | HC Wainwright & Co. | Buy | Maintains | $17.00 | |
| Oct 25, 2019 | Oppenheimer | Outperform | Initiates | $N/A | |
| Mar 26, 2018 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Mar 26, 2018 | HC Wainwright & Co. | Buy | Initiates | $N/A |
Essa Pharma Inc. (EPIX) Competitors
The following stocks are similar to Essa Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Essa Pharma Inc. (EPIX) Financial Data
Essa Pharma Inc. has a market capitalization of $9.52M with a P/E ratio of -0.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -21.3%.
Valuation Metrics
Market Cap
$9.52M
Enterprise Value
$-100,101,296
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+1,151.6%
Current Ratio
69.1x
Debt/Equity
0.0x
ROE
-21.3%
ROA
-15.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Essa Pharma Inc. (EPIX) Business Model
About Essa Pharma Inc.
What They Do
Develops therapies for prostate cancer treatment.
Business Model
Essa Pharma Inc. operates as a clinical-stage pharmaceutical company, focusing on developing small molecule therapies specifically targeting prostate cancer. The company's primary revenue potential lies in the successful development and commercialization of its proprietary compounds that inhibit the N-terminal domain of the androgen receptor, addressing the critical challenges of treatment resistance.
Additional Information
Headquartered in Vancouver, Canada, Essa Pharma is engaged in the oncology sector, aiming to improve patient outcomes through innovative treatments. The company actively collaborates with research partners to advance its clinical candidates and contribute to addressing significant unmet medical needs in cancer therapeutics.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
35
CEO
Dr. David Ross Parkinson M.D.
Country
Canada
IPO Year
2015
Website
www.essapharma.comEssa Pharma Inc. (EPIX) Latest News & Analysis
Latest News
Quick Summary
ESSA Pharma Inc. has completed its acquisition by XenoTherapeutics, as announced on October 9, 2025.
Why It Matters
The acquisition of ESSA Pharma by XenoTherapeutics may impact stock performance, strategic direction, and investor sentiment, influencing future growth potential and market positioning.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ESSA Pharma Inc. shareholders approved the acquisition by XenoTherapeutics Inc. with over 99% voting in favor at a special meeting held on October 6, 2025.
Why It Matters
The approval of ESSA Pharma's acquisition by XenoTherapeutics indicates strong shareholder confidence, which may lead to increased stock stability and potential growth opportunities for investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ESSA Pharma Inc. (NASDAQ:EPIX) held a shareholder/analyst call on October 3, 2025, featuring CEO David Parkinson and CFO David Wood, recorded for attendees.
Why It Matters
The shareholder call indicates potential updates on ESSA Pharma's strategic direction, financial health, and future prospects, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
South San Francisco and Vancouver, BC, are the locations mentioned in the news excerpt, but no specific financial information or developments were provided.
Why It Matters
The location specifies potential market opportunities or risks in the biotech sector, impacting stock valuations and investment strategies in the region.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Shareholders will receive about $0.12 per share in cash and up to $0.14 per CVR upon transaction closure. The special meeting is adjourned to October 3, 2025.
Why It Matters
Shareholders will receive cash and contingent value rights, indicating potential returns. The adjournment suggests ongoing negotiations or uncertainty, impacting stock volatility and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Discussions are ongoing regarding potential revised financial terms for a transaction with XenoTherapeutics, leading to an adjournment in negotiations.
Why It Matters
Adjournment signals potential changes in financial terms, which could impact the valuation and future profitability of the transaction with XenoTherapeutics, influencing investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EPIX Stock
What is Essa Pharma Inc.'s (EPIX) stock forecast for 2026?
Analyst forecasts for Essa Pharma Inc. (EPIX) are not currently available. The stock is trading at $0.20.
Is EPIX stock a good investment in 2026?
According to current analyst ratings, EPIX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EPIX stock?
Price predictions from Wall Street analysts for EPIX are not currently available. The stock is trading at $0.20.
What is Essa Pharma Inc.'s business model?
Essa Pharma Inc. operates as a clinical-stage pharmaceutical company, focusing on developing small molecule therapies specifically targeting prostate cancer. The company's primary revenue potential lies in the successful development and commercialization of its proprietary compounds that inhibit the N-terminal domain of the androgen receptor, addressing the critical challenges of treatment resistance.
What is the highest forecasted price for EPIX Essa Pharma Inc.?
Price targets from Wall Street analysts for EPIX are not currently available. The stock is trading at $0.20.
What is the lowest forecasted price for EPIX Essa Pharma Inc.?
Price targets from Wall Street analysts for EPIX are not currently available. The stock is trading at $0.20.
What is the overall EPIX consensus from analysts for Essa Pharma Inc.?
The overall analyst consensus for EPIX is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are EPIX stock price projections?
Stock price projections, including those for Essa Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 2:21 PM UTC